Letter to the editor17q12-21 variants interact with smoke exposure as a risk factor for pediatric asthma but are equally associated with early-onset versus late-onset asthma in North Americans of European ancestry
References (8)
- et al.
ORMDL3 variants associated with asthma susceptibility in North Americans of European ancestry
J Allergy Clin Immunol
(2008) - et al.
Asthma genetics 2006: the long and winding road to gene discovery
Genes Immun
(2006) - et al.
Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma
Nature
(2007) - et al.
Effect of 17q21 variants and smoking exposure in early-onset asthma
N Engl J Med
(2008)
Cited by (69)
Role of local CpG DNA methylation in mediating the 17q21 asthma susceptibility gasdermin B (GSDMB)/ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) expression quantitative trait locus
2018, Journal of Allergy and Clinical ImmunologyCat exposure in early life decreases asthma risk from the 17q21 high-risk variant
2018, Journal of Allergy and Clinical ImmunologyImmune development and environment: lessons from Amish and Hutterite children
2017, Current Opinion in ImmunologyLeveraging gene-environment interactions and endotypes for asthma gene discovery
2016, Journal of Allergy and Clinical ImmunologyPolymorphisms related to ORMDL3 are associated with asthma susceptibility, alterations in transcriptional regulation of ORMDL3, and changes in T<inf>H</inf>2 cytokine levels
2015, Journal of Allergy and Clinical Immunology
Disclosure of potential conflict of interest: J. H. Flory has received nonprofit grants from FOCUS, the University of Pennsylvania, and the National Institutes of Health. J. D. Christie receives grant support from the National Institutes of Health and has provided legal consultation/expert witness testimony in cases related to mesothelioma in brake workers. J. Allen receives grant support from the National Institutes of Health. J. Spergel receives grant support from Ception and is on the speakers' bureau for Schering-Plough and AstraZeneca. R. Grundmeier receives grant support from the Agency for Healthcare Research and Quality. M. Magnusson has provided legal consultation/expert witness testimony in cases related to medical malpractice. S. F. A. Grant receives grant support from the National Institutes of Health. H. Bisgaard has been a consultant to and paid lecturer for and holds sponsored grants from Aerocrine, Altana, GlaxoSmithKline, Merck, MedImmune, NeoLab, and Pfizer and has provided legal consultation/expert witness testimony on behalf of NeoLab. The rest of the authors have declared that they have no conflict of interest.